Plasma Fibroblast Growth Factor 23 Concentration Is Associated with Intracranial Cerebral Atherosclerosis in Acute Ischemic Stroke Patients
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Fibroblast growth factor 23 (FGF23) is associated with atherosclerosis via nitric-oxide-associated endothelial dysfunction and calcium-phosphate-related bone mineralization. This study aimed to determine the association of the plasma FGF23 concentration with intracranial cerebral atherosclerosis (ICAS) and extracranial cerebral atherosclerosis (ECAS). Methods We prospectively enrolled 262 first-ever ischemic stroke patients in whom brain magnetic resonance was performed and a blood sample acquired within 24 h after admission. Plasma FGF23 concentrations were measured using an enzyme-linked immunosorbent assay. The presence of ICAS or ECAS was defined as a ≥50% decrease in arterial diameter in magnetic resonance angiography. The burden of cerebral atherosclerosis was calculated by adding the total number of vessels defined as ICAS or ECAS. Results Our study population included 152 (58.0%) males. The mean age was 64.7 years, and the plasma FGF23 concentration was 347.5±549.6 pg/mL (mean±SD). ICAS only, ECAS only, and both ICAS and ECAS were present in 31.2% (n=82), 4.9% (n=13), and 6.8% (n=18) of the subjects, respectively. In multivariate binary and ordinal logistic analyses, after adjusting for sex, age, and variables for which p<0.1 in the univariate analysis, the plasma FGF23 concentration (per 100 pg/mL) was positively correlated with the presence of ICAS [odds ratio (OR)=1.07, 95% CI=1.00–1.15, p=0.039], burden of ICAS (OR=1.09, 95% CI=1.04–1.15, p=0.001), and burden of ECAS (OR=1.06, 95% CI=1.00–1.12, p=0.038), but it was not significantly related to the presence of ECAS (OR=1.05, 95% CI=0.99–1.12, p=0.073). Conclusions The plasma FGF23 may be a potential biomarker for cerebral atherosclerosis, particularly the presence and burden of ICAS in stroke patients.
Abstract
Background and Purpose Fibroblast growth factor 23 (FGF23) is associated with atherosclerosis via nitric-oxide-associated endothelial dysfunction and calcium-phosphate-related bone mineralization. This study aimed to determine the association of the plasma FGF23 concentration with intracranial cerebral atherosclerosis (ICAS) and extracranial cerebral atherosclerosis (ECAS). Methods We prospectively enrolled 262 first-ever ischemic stroke patients in whom brain magnetic resonance was performed and a blood sample acquired within 24 h after admission. Plasma FGF23 concentrations were measured using an enzyme-linked immunosorbent assay. The presence of ICAS or ECAS was defined as a ≥50% decrease in arterial diameter in magnetic resonance angiography. The burden of cerebral atherosclerosis was calculated by adding the total number of vessels defined as ICAS or ECAS. Results Our study population included 152 (58.0%) males. The mean age was 64.7 years, and the plasma FGF23 concentration was 347.5±549.6 pg/mL (mean±SD). ICAS only, ECAS only, and both ICAS and ECAS were present in 31.2% (n=82), 4.9% (n=13), and 6.8% (n=18) of the subjects, respectively. In multivariate binary and ordinal logistic analyses, after adjusting for sex, age, and variables for which p<0.1 in the univariate analysis, the plasma FGF23 concentration (per 100 pg/mL) was positively correlated with the presence of ICAS [odds ratio (OR)=1.07, 95% CI=1.00–1.15, p=0.039], burden of ICAS (OR=1.09, 95% CI=1.04–1.15, p=0.001), and burden of ECAS (OR=1.06, 95% CI=1.00–1.12, p=0.038), but it was not significantly related to the presence of ECAS (OR=1.05, 95% CI=0.99–1.12, p=0.073). Conclusions The plasma FGF23 may be a potential biomarker for cerebral atherosclerosis, particularly the presence and burden of ICAS in stroke patients.
참고문헌 (37)
- 방오영, "Intracranial Atherosclerosis: Current Understanding and Perspectives", 대한뇌졸중영문학회지, 16(1), pp.27~35 (2014), 대한뇌졸중학회[DOI]
- Arenillas JF, "High lipoprotein(a), diabetes, and the extent of symptomatic intracranial atherosclerosis", Neurology, 63, pp.27~32 (2004)
- Park KY, "Prevalence and risk factors of intracranial atherosclerosis in an asymptomatic Korean population", J Clin Neurol, 2, pp.29~33 (2006)
- Song TJ, "Is obstructive sleep apnea associated with the presence of intracranial cerebral atherosclerosis?", Sleep Breath, 21, pp.639~646 (2017)
- ADHR Consortium, "Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23", Nat Genet, 26, pp.345~348 (2000)
- Martin A, "Regulation and function of the FGF23", Klotho endocrine pathways, 2012, pp.92, 131~155
- Zoccali C, "FGF23 : a mature renal and cardiovascular risk factor?", Blood Purif, 36, pp.52~57 (2013)
- Donate-Correa J, "Pathophysiological implications of fibroblast growth factor-23 and Klotho and their potential role as clinical biomarkers", Clin Chem, 60, pp.933~940 (2014)
- Hu X, "Elevation in fibroblast growth factor 23 and its value for identifying subclinical atherosclerosis in first-degree relatives of patients with diabetes", Sci Rep, 6, pp.34696~ (2016)
- Shibata K, "Association between circulating fibroblast growth factor 23, αKlotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients", PLoS One, 8, pp.e73184~ (2013)
- Malyszko J, "FGF23 and Klotho in relation to markers of endothelial dysfunction in kidney transplant recipients", Transplant Proc, 46, pp.2647~2650 (2014)
- Ärnlöv J, "Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology", Clin J Am Soc Nephrol, 8, pp.781~786 (2013)
- Schoppet M, "Serum level of the phosphaturic factor FGF23is associated with abdominal aortic calcification in men : the STRAMBO study", J Clin Endocrinol Metab, 97, pp.E575~E583 (2012)
- 송태진, "Association between Aortic Atheroma and Cerebral Small Vessel Disease in Patients with Ischemic Stroke", 대한뇌졸중영문학회지, 18(3), pp.312~320 (2016), 대한뇌졸중학회
- 장윤경, "Interarm Blood Pressure Difference is Associated with Early Neurological Deterioration, Poor Short-Term Functional Outcome, and Mortality in Noncardioembolic Stroke Patients", Journal of Clinical Neurology, 14(4), pp.555~565 (2018), 대한신경과학회[DOI]
- 송태진, "High Dietary Glycemic Load is Associated with Poor Functional Outcome in Patients with Acute Cerebral Infarction", Journal of Clinical Neurology, 14(2), pp.165~173 (2018), 대한신경과학회[DOI]
- Adams HP Jr, "Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172in Acute Stroke Treatment", Stroke, 24, pp.35~41 (1993)
- Song TJ, "Association of plasma osteoprotegerin levels with stroke severity and functional outcome in acute ischaemic stroke patients", Biomarkers, 17, pp.738~744 (2012)
- Song TJ, "The distribution of cerebral microbleeds determines their association with arterial stiffness in non-cardioembolic acute stroke patients", Eur J Neurol, 21, pp.463~469 (2014)
- Levey AS, "Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate", Ann Intern Med, 145, pp.247~254 (2006)
- Samuels OB, "A standardized method for measuring intracranial arterial stenosis", AJNR Am J Neuroradiol, 21, pp.643~646 (2000)
- Kim J, "The association between cerebral atherosclerosis and arterial stiffness in acute ischemic stroke", Atherosclerosis, 219, pp.887~891 (2011)
- North American Symptomatic Carotid Endarterectomy Trial Collaborators, "Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis", N Engl J Med, 325, pp.445~453 (1991)
- Chang Y, "Interarm systolic and diastolic blood pressure difference is diversely associated with cerebral atherosclerosis in noncardioembolic stroke patients", Am J Hypertens, 31, pp.35~42 (2017)
- Lima F, "FGF-23 serum levels and bone histomorphometric results in adult patients with chronic kidney disease on dialysis", Clin Nephrol, 82, pp.287~295 (2014)
- Mirza MA, "Relationship between circulating FGF23 and total body atherosclerosis in the community", Nephrol Dial Transplant, 24, pp.3125~3131 (2009)
- Semba RD, "Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women", Clin J Am Soc Nephrol, 7, pp.85~91 (2012)
- Faul C, "FGF23 induces left ventricular hypertrophy", J Clin Invest, 121, pp.4393~4408 (2011)
- Kanbay M, "Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease", Clin J Am Soc Nephrol, 5, pp.1780~1786 (2010)
- Singh S, "Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease", Kidney Int, 90, pp.985~996 (2016)
- Xie D, "Role of high sensitivity Creactive protein and other risk factors in intracranial and extracranial artery occlusion in patients with ischaemic stroke", J Int Med Res, 43, pp.711~717 (2015)
- Lanske B, "Molecular interactions of FGF23 and PTH in phosphate regulation", Kidney Int, 86, pp.1072~1074 (2014)
- Rodriguez-Ortiz ME, "Calcium deficiency reduces circulating levels of FGF23", J Am Soc Nephrol, 23, pp.1190~1197 (2012)
- Kang K, "Serum calcium and phosphate concentrations and intracranial atherosclerosis", Atherosclerosis, 232, pp.249~253 (2014)
- Adeney KL, "Association of serum phosphate with vascular and valvular calcification in moderate CKD", J Am Soc Nephrol, 20, pp.381~387 (2009)
- Pini R, "Relationship between calcification and vulnerability of the carotid plaques", Ann Vasc Surg, 44, pp.336~342 (2017)
- Mirza MA, "Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community", Atherosclerosis, 205, pp.385~390 (2009)